Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 7:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 25 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Major Depressive Disorder
Interventions
Ketamine, Psychotherapy
Drug · Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 90 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Completed Phase 4 Interventional Results available

Helping Those With Mental Illness Quit Smoking

NCT01783912
Conditions
Smoking, Nicotine Dependence, Mental Disorders
Interventions
Cognitive / Motivational Individual Sessions, Attention Control Individual Sessions, Nicotine Patch, Group Curriculum
Behavioral · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 99 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
PTSD
Interventions
MDMA, Group Therapy
Drug · Behavioral
Lead sponsor
Portland VA Research Foundation, Inc
Other
Eligibility
18 Years to 64 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Vancouver, Washington
Conditions
Alcohol Use Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Stress Disorders, Post-Traumatic
Interventions
Motion-assisted, Multi-modular Memory Desensitization and Reconsolidation (3MDR)
Other
Lead sponsor
Uniformed Services University of the Health Sciences
Federal
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Stuttering
Interventions
Psilocybin, Speech therapy
Drug · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Conditions
PTSD and Trauma-related Symptoms
Interventions
Preparatory Session, Ketamine-assisted Psychotherapy Session #1, Ketamine-assisted Psychotherapy Session #2, Integration Session
Behavioral · Drug
Lead sponsor
Irma Fleming
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Completed Not applicable Interventional Accepts healthy volunteers Results available

An Exposure-Based Implementation Strategy to Decrease Clinician Anxiety Around Suicide Prevention

NCT05172609
Conditions
Implementation Science
Interventions
Exposure Based Implementation Strategy (EBIS), Implementation as Usual (IAU)
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Anorexia Nervosa
Interventions
Psilocybin, Preparation and Integration Sessions
Drug · Behavioral
Lead sponsor
Marissa Raymond-Flesch, MD, MPH
Other
Eligibility
18 Years to 25 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
San Francisco, California
Active, not recruiting Phase 1 Interventional

Effects of Repeated Psilocybin Dosing in OCD

NCT05370911
Conditions
Obsessive-Compulsive Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
New Haven, Connecticut
Conditions
Methamphetamine Use Disorder
Interventions
Ketamine, Psychotherapy
Drug · Behavioral
Lead sponsor
Nicky Mehtani, MD, MPH
Other
Eligibility
18 Years to 69 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Francicso, California
Completed Phase 2 Interventional Accepts healthy volunteers

Social Anxiety MDMA-Assisted Therapy Investigation

NCT05138068
Conditions
Social Anxiety Disorder
Interventions
MDMA, Psychotherapy
Drug · Behavioral
Lead sponsor
Jason B Luoma
Other
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Not yet recruiting Phase 2 Interventional

Psilocybin-Assisted Therapy

NCT07332143
Conditions
PTSD
Interventions
psilocybin, Supportive Therapy, Prolonged Exposure Therapy
Drug · Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
PTSD
Interventions
Ketamine Hydrochloride
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Conditions
Methamphetamine Use Disorder, Human Immunodeficiency Virus (HIV)
Interventions
Psilocybin 5 mg, Psilocybin 25 mg, Motivational Support
Drug · Behavioral
Lead sponsor
Nicky Mehtani, MD, MPH
Other
Eligibility
25 Years to 64 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Francisco, California
Active, not recruiting Phase 3 Interventional

Psilocybin for Major Depressive Disorder (MDD)

NCT06308653
Conditions
Depressive Disorder, Major
Interventions
Psilocybin 25 mg, Inactive Placebo, Psilocybin 5 mg, Psychosocial Support
Drug · Behavioral
Lead sponsor
Usona Institute
Other
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
29
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 25 more
Conditions
Bipolar II Disorder, Depression, Bipolar, Suicidality
Interventions
Psilocybin, Therapeutic Support
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
25 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Cancer
Interventions
Psilocybin
Drug
Lead sponsor
University of Utah
Other
Eligibility
25 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
PTSD
Interventions
MDMA, Cognitive Processing Therapy, MDMA-assisted Cognitive Processing Therapy (MDMA-aCPT)
Drug · Behavioral
Lead sponsor
Patricia Suppes
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Depressive Disorder, Major
Interventions
Psilocybin, Niacin, Set and Setting (SaS) Protocol
Drug · Other
Lead sponsor
Usona Institute
Other
Eligibility
21 Years to 65 Years
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
11
States / cities
San Francisco, California • Santa Monica, California • New Haven, Connecticut + 8 more
Recruiting Phase 2Phase 3 Interventional

Psilocybin Therapy in Advanced Cancer

NCT05398484
Conditions
Advanced Cancer
Interventions
Psilocybin 25 mgs, Niacin 100mg, Psychotherapy
Drug · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years to 100 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Aurora, Colorado • New York, New York
Conditions
PTSD, Stress Disorders, Traumatic, Stress Disorders, Post-Traumatic, Trauma and Stressor Related Disorders, Mental Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Ohio State University
Other
Eligibility
21 Years to 64 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Depression, Burnout, Professional
Interventions
Psilocybin, Mindfulness-Based Stress Reduction (MBSR)
Drug · Behavioral
Lead sponsor
University of Utah
Other
Eligibility
25 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Posttraumatic Stress Disorder, Traumatic Brain Injury
Interventions
Motion-assisted, Multi-modular Memory Desensitization and Reconsolidation (3MDR) Therapy
Behavioral
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland